Biological Assembly 1  

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 72.67 kDa 
• Atom Count: 5,106 
• Modelled Residue Count: 577 
• Deposited Residue Count: 628 
• Unique protein chains: 1

 7JU5

Structure of RET protein tyrosine kinase in complex with pralsetinib

• PDB DOI: 10.2210/pdb7JU5/pdb

• Classification: Transferase/Transferase inhibitor
• Organism(s): Homo sapiens
• Expression System: Spodoptera aff. frugiperda 1 BOLD-2017
• Mutation(s): No 


• Deposited: 2020-08-19 Released: 2020-11-11 
• Deposition Author(s): Terzyan, S.S., Shen, T., Wu, J., Mooers, B.H.M.
• Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.247 
• R-Value Work: 0.188 
• R-Value Observed: 0.191 

Literature

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Subbiah, V., Shen, T., Terzyan, S.S., Liu, X., Hu, X., Patel, K.P., Hu, M., Cabanillas, M., Behrang, A., Meric-Bernstam, F., Vo, P.T.T., Mooers, B.H.M., Wu, J.

(2021) Ann Oncol 32: 261-268

• PubMed: 33161056 
• DOI: 10.1016/j.annonc.2020.10.599
• Primary Citation of Related Structures:  
  7JU5, 7JU6


• PubMed Abstract: 
  

Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung cancer (NSCLC). It is critical to analyze RET mutants resistant to these drugs and unravel the molecular basis to improve patient outcomes.

---

Organizational Affiliation: 

Peggy and Charles Stephenson Cancer Center, Oklahoma City, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA. Electronic address: [e-mail].

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Proto-oncogene tyrosine-protein kinase receptor Ret	A, B	314	Homo sapiens	Mutation(s): 0  Gene Names: RET, CDHF12, CDHR16, PTC, RET51 EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P07949 (Homo sapiens) Explore P07949  Go to UniProtKB:  P07949
PHAROS:  P07949

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
Q4J (Subject of Investigation/LOI)	C [auth A], F [auth B]	Pralsetinib C27 H32 F N9 O2 GBLBJPZSROAGMF-BATDWUPUSA-N
FMT	D [auth A], E [auth A], G [auth B], H [auth B]	FORMIC ACID C H2 O2 BDAGIHXWWSANSR-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.247 
• R-Value Work: 0.188 
• R-Value Observed: 0.191 
• Space Group: P 1 2₁ 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 50.449	α = 90
b = 80.329	β = 100.25
c = 79.84	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
PDB_EXTRACT	data extraction
HKL-2000	data reduction
HKL-2000	data scaling
REFMAC	phasing

Structure Validation

Entry History & Funding Information

Deposition Data

• Released Date: 2020-11-11 
Deposition Author(s): Terzyan, S.S., Shen, T., Wu, J., Mooers, B.H.M.

---

Funding Organization	Location	Grant Number
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)	United States	P20GM103640

Revision History  

• Version 1.0: 2020-11-11
  Type: Initial release
  
• Version 1.1: 2020-11-25
  Changes: Database references
• Version 1.2: 2021-01-27
  Changes: Database references